Tandem Diabetes Care (TNDM) Property, Plant & Equipment (Net) Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 10.07% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 8.57% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 9.71% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 17.92% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 3.47% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 13.19% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 9.97% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 9.80% |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn | 3.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.73% |
| Dec 31, 2025 | 6.83% |
| Sep 30, 2025 | 2.24% |
| Jun 30, 2025 | 9.58% |
| Mar 31, 2025 | 16.59% |
| Dec 31, 2024 | 15.75% |
| Sep 30, 2024 | 17.78% |
| Jun 30, 2024 | 17.16% |
| Mar 31, 2024 | 15.40% |
| Dec 31, 2023 | 15.23% |
| Sep 30, 2023 | 15.38% |
| Jun 30, 2023 | 18.44% |
| Mar 31, 2023 | 25.61% |
| Dec 31, 2022 | 27.69% |
| Sep 30, 2022 | 37.46% |
| Jun 30, 2022 | 37.31% |
| Mar 31, 2022 | 42.76% |
| Dec 31, 2021 | 43.22% |
| Sep 30, 2021 | 41.32% |
| Jun 30, 2021 | 38.98% |
| Mar 31, 2021 | 38.81% |
| Dec 31, 2020 | 36.59% |
| Sep 30, 2020 | 34.46% |
| Jun 30, 2020 | 27.01% |
| Mar 31, 2020 | 21.60% |
| Dec 31, 2019 | 21.38% |
| Sep 30, 2019 | 17.35% |
| Jun 30, 2019 | 11.89% |
| Mar 31, 2019 | 2.53% |
| Dec 31, 2018 | 3.37% |
| Sep 30, 2018 | 5.70% |
| Jun 30, 2018 | 8.33% |
| Mar 31, 2018 | 13.41% |
| Dec 31, 2017 | 15.99% |
| Sep 30, 2017 | 18.01% |
| Jun 30, 2017 | 20.20% |
| Mar 31, 2017 | 24.62% |
| Dec 31, 2016 | 23.03% |